Having trouble accessing articles? Reset your cache.

Ad-IL-12: Phase II started

Ziopharm began a 2-part, open-label, U.S. Phase II trial to evaluate Ad-RTS-IL-12 plus palifosfamide in up to 68 patients with visible lesions or lesions

Read the full 242 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE